| Title |
Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
|
|---|---|
| Published in |
Frontiers in oncology, August 2016
|
| DOI | 10.3389/fonc.2016.00186 |
| Pubmed ID | |
| Authors |
Katharina I. Deeg, Inn Chung, Caroline Bauer, Karsten Rippe |
| Abstract |
Telomere maintenance is a hallmark of cancer as it provides cancer cells with cellular immortality. A significant fraction of tumors uses the alternative lengthening of telomeres (ALT) pathway to elongate their telomeres and to gain an unlimited proliferation potential. Since the ALT pathway is unique to cancer cells, it represents a potentially valuable, currently unexploited target for anti-cancer therapies. Recently, it was proposed that ALT renders cells hypersensitive to ataxia telangiectasia- and RAD3-related (ATR) protein inhibitors (Flynn et al., Science 347, 273). Here, we measured the response of various ALT- or telomerase-positive cell lines to the ATR inhibitor VE-821. In addition, we compared the effect of the inhibitor on cell viability in isogenic cell lines, in which ALT was active or suppressed. In these experiments, a general ATR inhibitor sensitivity of cells with ALT could not be confirmed. We rather propose that the observed variations in sensitivity reflect differences between cell lines that are unrelated to ALT. |
Twitter Demographics
The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Switzerland | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| United States | 1 | 2% |
| France | 1 | 2% |
| Unknown | 61 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 20 | 31% |
| Student > Master | 14 | 22% |
| Researcher | 7 | 11% |
| Student > Bachelor | 6 | 9% |
| Student > Doctoral Student | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 11 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 24 | 38% |
| Agricultural and Biological Sciences | 9 | 14% |
| Medicine and Dentistry | 8 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Engineering | 3 | 5% |
| Other | 4 | 6% |
| Unknown | 13 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2020.
All research outputs
#7,486,330
of 22,883,326 outputs
Outputs from Frontiers in oncology
#2,530
of 17,648 outputs
Outputs of similar age
#119,582
of 342,845 outputs
Outputs of similar age from Frontiers in oncology
#9
of 41 outputs
Altmetric has tracked 22,883,326 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 17,648 research outputs from this source. They receive a mean Attention Score of 2.6. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,845 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.